First TIL Results: Four Patients, All Responded, One Complete; Panel Pens Reauthorization Drive
In Brief: Lepovetsky Heads New NCI Office Of Technology Development; Temporary Now, Maybe Permanent
FDA Advisory Committee To Consider NDAs On Novantrone, HD MTX
ACS Modifies Pap Test Guidelines
Cancer Letter, PR Firm Settle Out Of Court On Copyright Violation
Comments Invited On Centers Program
Radiation Exposure Mostly Natural, NCRP Report Says
Trending Stories
- ACOG says it will no longer accept federal funding
- Gardiner Harris, acclaimed health care and pharma journalist, on his New York Times bestselling book
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - ANCHOR trial shows that treatment of anal high-grade squamous intraepithelial lesions prevents anal cancer in people with HIV
- FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills